Document and Entity Information - USD ($)
$ in Millions

12 Months Ended

Dec. 31, 2023

Mar. 06, 2024

Jun. 30, 2023

Cover [Abstract]

Document Type

10-K

Amendment Flag

false

Document Period End Date

Dec. 31, 2023

Document Fiscal Year Focus

2023

Document Fiscal Period Focus

FY

Trading Symbol

JANX

Security12b Title

Common Stock, $0.001 par value per share

Security Exchange Name

NASDAQ

Entity Registrant Name

Janux Therapeutics, Inc.

Entity Central Index Key

0001817713

Current Fiscal Year End Date

--12-31

Entity Filer Category

Non-accelerated Filer

Entity Well-known Seasoned Issuer

No

Entity Voluntary Filers

No

Entity Small Business

true

Entity Emerging Growth Company

true

Entity Ex Transition Period

true

ICFR Auditor Attestation Flag

false

Document Financial Statement Error Correction

false

Entity Public Float

$ 279.6

Entity Common Stock, Shares Outstanding

51,660,060

Entity Current Reporting Status

Yes

Entity Interactive Data Current

Yes

Entity Shell Company

false

Document Annual Report

true

Document Transition Report

false

Entity File Number

001-40475

Entity Incorporation, State or Country Code

DE

Entity Tax Identification Number

82-2289112

Entity Address, Address Line One

10955 Vista Sorrento Parkway, Suite 200

Entity Address, City or Town

San Diego

Entity Address, State or Province

CA

Entity Address, Postal Zip Code

92130

City Area Code

858

Local Phone Number

751-4493

Documents Incorporated by Reference

Portions of the Registrant’s definitive proxy statement for its 2024 Annual Meeting of Stockholders, which the Registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the Registrant’s fiscal year ended December 31, 2023, are incorporated by reference into Part III of this Annual Report on Form 10-K.

Auditor Name

Ernst & Young LLP

Auditor Firm ID

42

Auditor Location

San Diego, California